Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I’ll be looking to further support as well, albeit, probably in smaller doses. Good luck.
I don’t know what the share price will do in the near future, but I know the better our news gets, the more achievements that occur and the closer we get to commercialization, automation and combinations, the more price per share pressure this stock undergoes from negative outside forces. Those of us that are still here, and I can’t speak for everyone, hope that DCVax-l and the entire platform will make it through to the other side. There are many reasons to believe it will, in particular the science and long term survival in monotherapy, monotherapy plus SOC, the apparent imminently chosen formula with poly-iclc, and future combinations with CIs and other immunotherapies. Presently, it should start with monotherapy in rGBM and SOC + DCVax-l in nGBM.
All I said was good luck and best wishes to someone who is selling/leaving the stock. Not certain why that requires me to go back to the basics. This has been a long road*, and it’s taking more time than some people have. I’m still here.
* Well over a decade for several investors.
Good luck and best wishes with your other investments. Thank you for drawing our attention to the statistical side of things.
I think AngeloFoca was trolling for you with Booth bait.
I asked DI, via email, if they are going to let the public know when NWBO has received the commercial (GMP) material grade Flaskwork’s machines from their contractor.
Hopefully he’ll get back to me.
Continued:
Forgot to post patent application link. Note the difference between date of application and date of publication.
https://patentscope.wipo.int/search/en/detail.jsf?docId=US427665888&_cid=P11-LVE1OZ-12071-1
Reminder: NWBIO February 6, 2024
“The special difficulty involved in developing the Flaskworks machine was that, unlike other cell types, the dendritic cells tightly adhere to the surface of the culture vessel (similar to barnacles). Extracting them from inside the culture vessel without damaging the cells or reducing the yield of doses was extremely challenging. Other cells (including T cells) are generally cultured suspended in liquid in a bag, which makes it much easier to move them through processes. Many companies have developed or are developing machines to handle such other cell types – but not adherent cells. [Note: Flaskworks solved this challenge]
The tight adherence of dendritic cells is essential for 3 main reasons:
(a) to isolate the specific desired cell population and remove others,
(b) to assess the health of the patient’s immune cells (if the cells do not adhere tightly, they are likely not healthy) and
(c) to start the activation of the dendritic cells (the adherence triggers the start of activation).”
Very Interesting.
#dcvax $nwbo #gbm
— Peter Davis (@peter_brit) April 24, 2024
Another patent I have not seen before published November 2023. One of the longest titles I have ever seen 🤣This is from the Brazil office.
BRUS2016051781 - IN VITRO METHOD FOR DETERMINING THE IMMUNOTHERAPEUTIC POTENCE OF A COMPOSITION OF ACTIVE AND NOT… pic.twitter.com/iXgLapeqgP
Update on hyperactived dendritic cells IP.
#dcvax $nwbo #gbm @HenryMuney
— Peter Davis (@peter_brit) April 24, 2024
US20240122975 - IN VITRO METHODS AND COMPOSITIONS FOR ENHANCING THE ACTIVATION OF DENDRITIC CELLS AND T CELLS, AND FOR INDUCING A TH-1 IMMUNE RESPONSE.
Found it interesting that with the US the patent was just updated to reflect Publication, but… pic.twitter.com/nm1zLeCP1M
”It appears NICE times their meetings with estimated approval timelines, but if the approval timeline is slower than expected, NICE can still hold a closed meeting to make reimbursement decision(s) in private.” — HM
Some interesting language used on a recent NICE update that sheds light on the timing discussed in your email:
— hoffmann6383 (@hoffmann6383) April 23, 2024
"The appraisal committee meeting for ID4043 lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease, will go ahead on 9 May… pic.twitter.com/nEOdYA6ICh
Thanks to Peter Davis for finding this.
In our 25th year, Dame June Raine, CEO of @MHRAgovuk, highlights NICE's pivotal role as a key partner.
— NICE (@NICEComms) April 23, 2024
Together, we strive for timely access to the best care, embracing new science and tech, real-world evidence, quality standards and outcome-focused decisions.#NICE25 pic.twitter.com/atmJLZPV9g
Please keep your trench coat buttoned. This is a family friendly message board.
Exposing Crooks — inquirig
“Curious….” Not really.
NWBO already presented results that were then later published in JAMA.
DCVax-l is currently undergoing regulatory review for potential approval at this juncture.
What would NWBO present this year at NYAS?
You went from calling yourself a flopper, to calling me one, and now ask me to critique the bearded lady and the man with three buttocks. I won’t do it.
As for NWBO, you haven’t paid attention enough to know when I’ve critiqued them. For example, at the present time, I sincerely hope they are not letting the MM case and/or Eden interfere in any way with MAA approval decision timing.
Don’t be so hard on yourself.
So now you know, you can’t argue acceptance/validation hasn’t occurred if they are in the midst of responding to a (possible) RFI that would have been issued 80 days after validation.
This is where you are supposed to say, “Sorry for any confusion I may have caused, I am an AI and still learning, please be patient.”
You are very confused. An RFI (if one was issued), which you claimed at one point they are in the midst of, comes after acceptance/validation. In fact it comes 80 fricking days after acceptance/validation, and yet you also claim acceptance/validation has not occurred yet. You should have taken Monday off. Just put your keyboard away for a while.
First you say it’s likely in RFI mode, and five minutes later you state it hasn’t been accepted yet. Does not compute.
That is not necessarily inconsistent, if an RFI was issued.
“Likely still in RFI mode”
You couldn’t know one way or the other, which makes your certainty look very very stupid.
I easily could be wrong, but it seems to me (possibly) avoiding a CHM formal meeting, avoiding publicly stating NICE timeline progress and generally reducing the number of parties reviewing DCVax-l presently, that the chance for leaks was/is greatly reduced.
CNBC went back to real time NWBO pps towards end of trading day on Friday, but has now returned to 15 minute delay. They seemed to enjoy making certain investors saw Friday’s pps dip in real time.
Advent soon becomes somewhat archaic for NWBO’s purposes. You guys are way overestimating its future manufacturing worth and leverage once NWBO’s Flaskworks is in full swing. Sure, Advent could provide workers, expertise and space, but that’s hardly the behemoth you all make it out to be.
Thanks for reporting back.
I think there is a tendency to project how they will deal with revimmune’s patent interest in the dc + ci patent.
IMO, LP would have had that worked out in some agreement of understanding with the three or four main parties back when she had the patent app filed in 2015.
I simply can’t worry about these things. I assume it’s just a very good thing Europe, in addition to a few countries outside Europe, already granted the combination patent.
Thank you.
CNBC returns to giving NWBO pps in realtime. Chart not working very well though.
Thank you.
Once an original Eden prototype is selected, what is harder to mass produce, the mechanical features, the disposable parts or the programmed microchips?
With manufacturing (as opposed to product), normally, if MHRA approved Eden first, any FDA reciprocal recognition would be smoother, imo.
Typo: GMP
Who here thinks the commercial (gmo) grade units have been sent to Sawston by now?
Hey you wood chucks, stop chucking my wood!
Google Gemini
T+1: This means that after a trade, the settlement (delivery of shares and payment) needs to happen in one business day instead of the current two (T+2).
Illegal Shorting: This involves selling borrowed shares without proper disclosure or with the intent to not repurchase them, manipulating the stock price downward. T+1 doesn't address the legality of shorting itself, but it could potentially make illegal shorting more difficult by:
*Reducing the time window for illegal maneuvers.
*Increasing pressure to locate borrowable shares due to quicker settlement.
Failures to Deliver (Ftds): These happen when a seller cannot deliver the promised shares on settlement day. T+1 might lead to a temporary increase in FTDs initially as market participants adjust. However, the SEC believes their existing regulations are sufficient to handle these.
Overall, T+1 aims to improve efficiency and reduce risk in settlements. While it might indirectly make some illegal activities trickier, it's not a direct solution for addressing them.
Actually, because the final motion deadline is not until June 14, (which defendant’s will surely wait for), it makes sense for Laura Posner to wait until May 31 to file her response.
May 1, 2024: MTD + Support Docs (25 pages)
May 31, 2024: NWBO’s opposition (25 pages)
June 14, 2024: Defendant's reply (10 pages)
Next questions. Will T+1 catch/trap more naked shorts?
Will there be more FTDs after a stock has a massively positive event that carries over for at least two days of trading?
I should have said, how does t+1 effect the good faith free rider rule.
It appears, though I could be wrong,
After May 28, 2024, the scenario below would apparently no longer violate the good faith free rider prohibition, because they waited until Day 2 (aka T+1)?
What is a Good Faith Violation?
A good faith violation is the purchase of a security with unsettled funds, and subsequent sale of that security before the proceeds funding that purchase have settled.
Example:
Day 1 Sell 100 XYZ @ 20
Day 1 Buy 100 ABC @ 10
Day 2 Sell 100 ABC @ 15
The purchase of ABC is made using unsettled proceeds generated by the sale of XYZ, which will not settle until Day 3. Because the ABC is sold prior to settlement of the XYZ proceeds used to make that purchase, the sale results in a Good Faith Violation.
How does this impact avoiding the “free rider” prohibition. Does it mean when you sell a stock, and buy a stock immediately thereafter, that you can then sell that newly purchased stock the next day?